The immune receptor NOD1 may be a prime target for preventing or treating H. pylori infections — the most significant risk factor for stomach cancer, Vanderbilt researchers have discovered.

Mark Boothby and colleagues are exploring the factors that contribute to antibody production and quality, which are key to our defense against pathogens and response to vaccines.

Austin Kirschner and colleagues demonstrate how a hormone therapy for prostate cancer improves radiation’s tumor-killing power.

Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular "inboxes" that are targeted by up to half of all pharmaceuticals.

Jonathan Schoenecker and colleagues have discovered a new mechanism for the formation of bone in soft tissues — a complication of severe injuries that causes pain and limits mobility.

Vanderbilt researchers led by Eric Skaar are probing the mechanisms bacteria use when faced with nutrient starvation — a host defense strategy called “nutritional immunity.”

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.